Lotus Pharmaceuticals, NRx Pharmaceuticals and Alvogen have entered a global collaboration deal to develop and commercialise NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD).
Lotus will purchase global rights for NRX-101 and handle the commercialisation activities of the product in markets outside the US.
Go deeper with GlobalData
The company will collaborate with Alvogen to commercialise NRX-101 in the US through the Almatica label, the CNS-focused division of Alvogen.
Lotus and Alvogen will also provide funding for the next registrational trial to support NRX-101’s approval.
They will have a right to negotiate for new indications for NRX-101 outside the field of suicidal bipolar depression and/or potential new products comprising D-cycloserine along with an antidepressant/antipsychotic.
See Also:
NRx Pharmaceuticals will receive an initial payment of $10m on obtaining successful findings from the ongoing Phase IIb/III clinical trial and on completion of a Type B meeting with the US Food and Drug Administration (FDA).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company will receive a further $5m on gaining US FDA approval for NRX-101, and $330m milestone payments on reaching net sales targets.
It will also be eligible for a royalty on net sales between 12% and 16%, contingent upon meeting sales thresholds in the US market, and for payments based on the success of the product in other global markets.
NRx Pharmaceuticals CEO Stephan Willard stated: “This collaboration can accelerate the delivery of NRX-101 to patients grappling with suicidal bipolar depression who desperately need better treatment alternatives.
“This global partnership significantly minimises the need for future capital raises for NRX-101 development and commercialisation.”
